OMNICLOUDS/VERSA
14.9.2020 13:57:10 CEST | Business Wire | Press release
OmniClouds, the leading innovator in the cloud service provider (CSP) space and migrator for the EMEA region, today announced that it has adopted the Versa Secure SD-WAN solution to offer and expand services across the globe, using OmniClouds’ comprehensive SDN-dedicated network offering a unique experience of true SLA-based cloud services.
OmniClouds platform connects its enterprise customers’ branches and remote users to multiple public and private clouds, lowering the expense and complications of cloud adoption Globally. It is offering Versa Networks, the leader in Secure SD-WAN providing software-defined networking over any type of connectivity for simplified management and dynamic support for cloud adoption and migration.
OmniClouds will not only provide full hybrid cloud connectivity but will also use Versa Networks as an overlay to existing connectivity technologies, such as IP-MPLS, microwave, satellite, LTE or public internet, to automate operations and enhance connectivity over large geographic regions. This will give its enterprise, government and SME customers a central management view of the entire network, enabling them to easily control security, user permissions and parameters, such as latency and quality of service.
OmniClouds will use Versa Cloud Gateways at each of the regions’ and counties’ main cloud service providers, which connect with Secure SD-WAN CPE running Versa Operating System (VOS™) at the enterprises’ data centers, headquarters and branch operations. This dramatically reduces customer operating costs, smooths their adoption of cloud services, and enables widespread connectivity across distant locations.
Amr A Eid, Group Chief Executive Officer and Board Member, OmniClouds, said: “OmniClouds is excited and proud of the strategic partnership with Versa Networks, the best in class for SD-WAN Technologies. We are a partner led global organization, addressing our SME, Public Sector and SOHO customers through our regional, local, white label ISPs across the globe. In doing so we look for strong partnerships for our network technology and visionary and trustworthy leadership, and Versa Networks is exceptional in all these aspects. We are confident that we are setting the standard for both cloud connectivity and smart applications management.”
“OmniClouds is a leader in optimizing, migrating, and supporting organizations’ migration from traditional internet connectivity models to modern, cloud-based network infrastructures,” said Kelly Ahuja, CEO of Versa Networks. “Secure SD-WAN is the pervasive method for businesses and organizations to securely, reliably, and seamlessly connect their offices, teleworkers, employees, staff, and partners globally to private data centers, cloud services, and SaaS. Versa is excited to be working with OmniClouds to deliver the best-of-breed solution for the growing Middle East and Africa regions.”
Versa Networks, VOS, and Versa Titan are or may be registered trademarks of Versa Networks, Inc. All other marks and names mentioned herein may be trademarks of their respective companies.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005470/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom